
Opinion|Videos|October 7, 2024
Dravet Syndrome: Comorbidities and Patient Quality of Life
Author(s)M. Scott Perry, MD
Key Takeaways
- Dravet syndrome comorbidities include developmental delays, behavioral issues, sleep disturbances, and increased infection risk, requiring comprehensive management strategies.
- Multidisciplinary management involves pharmacological interventions, behavioral therapies, and supportive care to address the diverse needs of patients.
Scott Perry, MD, discusses how pediatric patients with Dravet syndrome often experience various comorbidities alongside seizures, including developmental delays, behavioral issues, and sleep disturbances, which significantly impact quality of life, especially when diagnosis is delayed, necessitating comprehensive management strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What comorbidities do pediatric patients with Dravet syndrome experience?
- How are these comorbidities managed?
- What is the effect of Dravet syndrome on a patient’s quality of life?
- How does a delayed diagnosis affect a patient's quality of life?
Advertisement
Related to this article

Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.

A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.

A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.

An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
2
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
3
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
4
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
5


